Albion Crown VCT Plc (CRWN) Ordinary 1p
Sell:28.00p
Buy:29.40p
0
Change:
No change
No change
Market closed |
Prices as at close on 31 October 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- This stock can be held in a
Sell:28.00p
Buy:29.40p
Change:
No change
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Market closed |
Prices as at close on 31 October 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:28.00p
Buy:29.40p
Change:
No change
No change
Market closed |
Prices as at close on 31 October 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Objective
The Company will invest in a broad portfolio of smaller, unquoted growth businesses across a variety of sectors including higher risk technology companies. Investments may take the form of equity or a mixture of equity and loans.
| Security | Weight |
|---|---|
| Arecor Therapeutics plc ORD GBP0.01 | 0.05% |
| Healios | 0.00% |
| Greenenerco | 0.00% |
| Sector | Weight |
|---|---|
| Healthcare | 0.05% |
| Country | Weight |
|---|---|
| United Kingdom | 0.05% |
Fee Structure
Management fee is 2% of NAV p.a.. Incentive fee is 20% p.a. of the amount by which the actual growth in NAV exceeds the target growth in NAV of not less than the base rate of RBS plus 2%. Contract is terminable on 12 months notice.
Dividend Policy
It is expected that dividends, if any, will be announced in April and October and paid in July and December each year,targeting an annual dividend yield of 5% on the prevailing NAV.. The dividend objective of the Board is to provide shareholders with a regular dividend flow.
ASSET SPLIT
Trust Manager
Not currently available for this investment trust.
Manager Bio
Not currently available for this investment trust.
Board Of Directors
Richard GloverChairman, Richard Wilson, Dorothy Berresford, Pamela Garside, Ian Spence
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.